Last reviewed · How we verify
Placebo Only Product in Oral Dose Form
Placebo Only Product in Oral Dose Form is a Small molecule drug developed by University of Southampton. It is currently in Phase 3 development for Clinical trial control comparator (not a therapeutic product).
A placebo product contains no active pharmaceutical ingredient and produces therapeutic effects solely through placebo response mechanisms.
A placebo product contains no active pharmaceutical ingredient and produces therapeutic effects solely through placebo response mechanisms. Used for Clinical trial control comparator (not a therapeutic product).
At a glance
| Generic name | Placebo Only Product in Oral Dose Form |
|---|---|
| Sponsor | University of Southampton |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo-only products are inert formulations used as control comparators in clinical trials to measure the effect of patient expectation, clinical attention, and natural disease progression independent of active drug effects. In Phase 3 trials, placebos establish the baseline therapeutic response attributable to non-pharmacological factors, allowing researchers to isolate the true efficacy of investigational treatments.
Approved indications
- Clinical trial control comparator (not a therapeutic product)
Common side effects
- Placebo response (symptom improvement without active ingredient)
- Nocebo response (adverse events attributed to inert substance)
Key clinical trials
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients. (PHASE2)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease (PHASE1)
- Dual Orexin Antagonism and Emotion and Affective Processing Study (PHASE4)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults (PHASE1)
- Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Only Product in Oral Dose Form CI brief — competitive landscape report
- Placebo Only Product in Oral Dose Form updates RSS · CI watch RSS
- University of Southampton portfolio CI